Ninenovo

Ninenovo (Beijing) Technology is a clinical-stage biotechnology company focused on the development of high-end complex formulations and long-acting injectable drug delivery systems. The company utilizes its proprietary microsphere and lipid-based technology platforms to create improved versions of established therapeutics, primarily targeting the central nervous system, metabolic diseases, and oncology. Ninenovo's lead programs include long-acting formulations of risperidone and rotigotine, which are designed to improve patient adherence and therapeutic outcomes in schizophrenia and Parkinson's disease. By specializing in difficult-to-manufacture complex injections, the company addresses significant barriers in chronic disease management and drug delivery. Ninenovo aims to become a global leader in the field of long-acting drug delivery through continuous innovation and robust manufacturing capabilities.